Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy.

Slides:



Advertisements
Similar presentations
Neoadjuvant therapy for Rectal cancer
Advertisements

Adjuvant chemotherapy in resectable liver-limited metastasis colorectal cancer 指導VS: 鄧豪偉 財團法人台灣癌症臨床研究發展基金會.
Post-operative Radiotherapy for Esophageal Cancer Parag Sanghvi, M.D., M.S.P.H. Department of Radiation Medicine Esophageal Care Conference 3/26/2007.
Carcinoma of the Cardia: Is there progress in the management of non-Barrett’s cancer Spanish Association of Surgeons Madrid 11 November 2002 The University.
DEBATE: What is the Optimal Sequence of Therapies for Stage II-III Adenocarcinoma of the Proximal Stomach? Michael A. Choti, MD Department of Surgery UT.
CHEMOTHERAPY AND BLADDER CANCER Walter Stadler, MD, FACP University of Chicago.
CA Esophagus – Role of Chemoirradiation WH Chan Pamela Youde Nethersole Eastern Hospital.
Controversies in Adjuvant Therapy for Pancreatic Cancer Parag Sanghvi M.D. Tasha McDonald M.D. Department of Radiation Medicine OHSU.
Joint Hospital Surgical Grand Round KL FOK NDH/AHNH Department of Surgery.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Postoperative Radiation for Oral Cavity Squamous Cell Carcinoma: The EP.
Management of Colorectal Liver Metastasis
Esophageal Cancer, New updates in Chemoradiation Dr Hamid Reza Dehghan Manshadi Radiation Oncologist Iran University of Medical sciences.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Dr. LP Si Tseung Kwan O Hospital. Introduction CA stomach is the 4 th most commonly diagnosed malignancy worldwide 2 nd most common cause of cancer-related.
Neoadjuvant Adjuvant Curative Palliative Neoadjuvant Radiation therapy the results of a phase III study from Beijing demonstrated a survival benefit.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Upper gastrointestinal cancers
Controversies in the management of PSA-only recurrent disease Stephen J. Freedland, MD Associate Professor of Urology and Pathology Durham VA Medical Center.
PREOPERATIVE HYPOFRACTIONED RADIOTHERAPY IN LOCALIZED EXTREMITY/TRUNK WALL SOFT TISSUE SARCOMAS EARLY STUDY RESULTS Hanna Kosela; Milena Kolodziejczyk;
AATS Postgraduate Course April 26, 2015 N2 - Current Evidence: Is There Role for Surgery? Is There a Role for Postop Radiation for Surprise N2? Linda W.
Sequential vs. concurrent chemoradiotherapy for locally advanced non-small cell carcinoma.
Intergroup trial CALGB 80101
National Oesophago–Gastric Cancer Audit Key Findings from 2014 Annual Report and Progress Report Georgina Chadwick Clinical Research Fellow.
Long-term follow-up of a prospective trial of pre-operative external-beam radiation and post-operative brachytherapy for retroperitoneal sarcoma LA Mikula,
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Specialist surgery “Some surgeons perform less than optimal surgery. Some are less competent technically than their colleagues; and some fail to supervise.
Background  Reports of long-term survivors (≥5 years) of locally advanced esophageal cancer (LAEC) have focused mainly on HRQL or GI symptoms  Only.
The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.
Targeted Intraoperative Radiotherapy versus Whole Breast Radiotherapy for Breast Cancer (TARGIT-A Trial): An International, Prospective, Randomised, Non-Inferiority.
A systematic meta-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft-tissue sarcoma Nabeel Pervaiz Nigel.
SYNCHRONOUS COLORECTAL AND LIVER RESECTION J Peter A Lodge MD FRCS HPB and Transplant Unit St James’s University Hospital Leeds LS9 7TF 2006 Association.
Gastric Cancer Gidon Almogy MD Department of General Surgery Hadassah University Hospital.
Individual patient data-based meta- analysis assessing the interest of pre- operative chemotherapy in resectable oesophageal carcinoma Abstract: 4512 Thirion.
Transanal Endoscopic Operation Indication – Technique – Results M. Sailer Department of Surgery Bethesda Hospital – Hamburg, Germany.
Preoperative chemoradiotherapy and postoperative chemotherapy with 5-FU and oxaliplatin versus 5-FU alone in locally advanced rectal cancer: First results.
MANAGEMENT OF ESOPHAGEAL CANCER Elshami Elamin, MD Medical Oncologist Central Care Cancer Center Newton, KS - USA.
Effect of preoperative concurrent chemoradiotherapy on survival of patients with resectable esophageal or esophagogastric junction cancer: Results from.
THE OUTBACK TRIAL A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared.
Adjuvant chemotherapy in Rectal Cancer?. What is the evidence for adjuvant chemotherapy? Do patients achieving a pathological complete response need chemotherapy?
RADIOTHERAPYin VULVAR CANCER 2013 ANZGOG Kailash Narayan.
Management of the primary in Stage IV colorectal cancer Erin Kennedy, MD, PhD, FRCSC Colorectal Surgery Mount Sinai Hospital University of Toronto.
Health-related quality of life in patients with oesophageal- and gastric cancer Lovisa Backemar, MD Surgical Care Sciences Department of Molecular Medicine.
P53 adapted neoadjuvant therapy for esophageal cancer: Pilot study Gastrointestinal (Non colorectal) cancer Poster discussion session Sat, June 2, 2007.
Therapeutic Delay and Survival after Surgery for Cancer of the Pancreatic Head with or without Preoperative Biliary Drainage Eshuis, van der Gaag, Rauws.
Poster # 18, abstract # 4530 Long term results of a phase III study investigating chemoradiation with and without surgery in locally advanced squamous.
Journal Club Dr. Eyad Al-Saeed Radiation Oncology 12 January, 2008.
The Role of Preoperative Approaches in Localized Gastro Esophageal Cancers David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan-Kettering.
Early Treatment of Relapsed Ovarian Cancer Based on CA125 Level Alone Versus Delayed Treatment Based on Conventional Clinical Indicators Results of the.
Carboplatin Not Inferior to Radiation as Adjuvant Therapy for Stage I Seminoma Slideset on: Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose.
Neoadjuvant treatment of borderline resectable and non-resectable pancreatic cancer V. Heinemann*, M. Haas & S. Boeck Annals of Oncology 24: 2484–2492,
Adjuvant and Neoadjuvant Therapy in Non- Small Cell Lung Cancer Seminars in Oncology 2oo5;32 (suppl 2):S9-S15 Kyung Hee Medical Center Department of Thoracic.
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
ADJUVANT CAPECITABINE AND OXALIPLATIN FOR GASTRIC CANCER AFTER D2 GASTRECTOMY (CLASSIC): A PHASE 3 OPEN-LABEL,RANDOMISED CONTROLLED TRIAL Yung-Jue Bang*,
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal- cell carcinoma after radical nephrectomy: phase III,
Oesophageal brachytherapy
Definitive Analysis of the Primary Outcomes
นายแพทย์ธราธร ตุงคะสมิต นายแพทย์ชำนาญการพิเศษ โรงพยาบาลมะเร็งอุดรธานี
Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.
What is the optimal pre-op therapy for esophagus and GE junction cancers?
Oesophageal and Gastric cancer: neo-adjuvant therapy
Adjuvant Radiation is Required for Gastric Cancer
Adjuvant Therapy in Gastric Cancer: Radiation Therapy Adds Nothing!
Neoadjuvant Adjuvant Curative Palliative
What’s new in stage III lung cancer?
THE LANCET Oncology Volume 19, No. 1, p27–39, January 2018
Presentation transcript:

Delivering clinical research to make patients, and the NHS, better OG neoadjuvant therapy Brachytherapy Stephen Falk dd/mm/yyyy

OG therapy 1. Neoadjuvant chemoradiation prior to curative surgery. 2. Brachytherapy for palliation. Trials to be published at ASCO 2015 OE 05 Adjuvant therapies ST 03 Adjuvant therapies All well designed trials that can change international practice

3

Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Homs MY et al. Lancet 2004 Oct 23-29;364(9444): Treatment / Results (n=209): Stent placement (n=108) single-dose (12 Gy) brachytherapy (n=101) Dysphagia improved more rapidly after stent placement than after brachytherapy, but long-term relief of dysphagia was better after brachytherapy. Stent placement had more complications (36 [33%] of 108 vs. 21 [21%] of 101; p=0.02). Groups did not differ for persistent or recurrent dysphagia (p=0.81), or for median survival (p=0.23).

Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Bergquist H et al. Dis Esophagus 2005;18(3): Ultraflex expandable stent or HDR endoluminal brachytherapy with 7 Gy x 3 given in 2-4 weeks Endpoints: Clinical assessment and health-related quality of life (HRQL) were measured at inclusion and 1, 3, 6, 9 and 12 months later Results (n=65): For stent group significantly better HRQL scores for dysphagia (P < 0.05) at the 1-month follow-up, but most other HRQL scores, including functioning and symptom scales deteriorated. Among brachytherapy-treated patients, improvement was found for the dysphagia-related scores at 3-months follow-up. No difference in median survival

Endoluminal stent group: rapid relief of dysphagia is seen within 2 weeks of treatment initiation, with 85% of patients being able to achieve a dysphagia score of 0 or 1. In the radiation therapy group [brachytherapy or external-beam (EBRT)], an initial lag period of 6–8 weeks is observed before effective relief of dysphagia is noted. The percentage of patients who achieve a dysphagia score of 1 or 0 at the 10-week follow-up is higher with brachytherapy (85%) and with EBRT (90%), than with stenting (72% Palliation

Brachytherapy for palliation ABS guidelines –Palliative treatment: Patients with adeno- or squamous cancers of the thoracic esophagus with distant metastases or unresectable local disease progression/recurrence after definitive radiation treatment should be considered for brachytherapy with palliative intent. 7

Individual Patient Data-based Meta-analysis Assessing Pre-operative Chemotherapy in Resectable Oesophageal Cancer Thirion P et al. Abstr. 4512, ASCO 2007

Current Status 0E05 Between January 2005 and October 2011, 897 patients were randomised from 70 UK centres. The primary outcome measure is overall survival, and will be reported at ASCO 2015.

OE05 summary 411 CF (91%) and 386 ECX (86%) patients had surgery. Four patients (2 in each arm) did not receive any protocol treatment. Overall, 379 CF (84%) and 308 ECX (69%) received all planned chemotherapy cycles and underwent a resection. 47 (5% in each arm) had an open and close operation. # Resection rates, surgical complications and 90 day post-operative mortality rates were similar.

MRC OEO2 vs INT113 OEO2INT113 surgical resection C+S92%80% S97%96% complete surgical resection C+S78%62% (path) S70%59% Inoperable C+S13%24% S17%11%

OEO5 conclusions Eagerly await survival and full surgical data This data says 4 cycles of chemotherapy safe and tolerable Will become the standard of care of pre-operative chemo therapy The outstanding questions are –Appropriate patient selection –Tri or bi-modality therapy.

Peri-operative Chemotherapy of Gastric Cancer: MAGIC trial Post-operative complications rates: similar –(CSC 47% S 45%), –as were deaths within 30 days of surgery 5-year survival rates: –Chemo+surgery:36% (30-43%) –surgery alone: 23% (17-29%)

ST03 projected accrual

ST03 Updated anastomotic leak numbers Oesophago-gastrectomy patients only

CROSS trial 368 patients, –275 (75%) had adenocarcinoma, –84 (23%) had squamous-cell carcinoma, and –7 (2%) had large-cell undifferentiated carcinoma R0 resection was achieved in –92% of patients in the chemoradiotherapy–surgery group versus –69% in the surgery group (P<0.001). Pathological complete response was achieved in –(29%) who underwent resection after chemoradiotherapy. –Postoperative complications were similar –in-hospital mortality was 4% in both. Median overall survival was –49.4 months in the trimodality group versus –24.0 months in the surgery group. (hazard ratio, 0.657; 95% confidence interval, to 0.871; P=0.003). 16

Trials DEBIOC CROSS v MAGIC ST03 sub-study Currently bulky T3/4 tumours type 1 and 2 predicted by EUS and CT 17